Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed Papers

Building a better sphingosine kinase-1 inhibitor.
Noninvasive molecular imaging of neuroinflammation.
Switching From Natalizumab to Fingolimod in Multiple Sclerosis: A French Prospective Study.
Fulminant Central Nervous System Nocardiosis in a Patient Treated With Alemtuzumab For Relapsing-Remitting Multiple Sclerosis.
Posterior reversible encephalopathy syndrome masquerading as progressive multifocal leukoencephalopathy in rituximab treated neuromyelitis optica.
Therapeutic laquinimod treatment decreases inflammation, initiates axon remyelination, and improves motor deficit in a mouse model of multiple sclerosis.
Motor programme activating therapy influences adaptive brain functions in multiple sclerosis: clinical and MRI study.
The impact of environmental infections (parasites) on MS activity.
Quantitative assessment of multiple sclerosis using inertial sensors and the TUG test.
Submembranous cytoskeletons stabilize nodes of Ranvier.
1,25-Dihydroxyvitamin D3 selectively and reversibly impairs T helper-cell CNS localization.
Characterization of human platelet binding of recombinant T cell receptor ligand.
Vitamin D: a natural inhibitor of multiple sclerosis.
New Drug Review 2010: Ustekinumab (Stelara, Centocor Ortho Biotech)
A randomized blinded trial of combination therapy with cyclophosphamide in patients-with active multiple sclerosis on interferon beta.
Structure and Activity of the Acid Sensing Ion Channels.
Alemtuzumab for multiple sclerosis: Long term follow-up in a multi-centre cohort.
COMPARE: pharmacokinetic profiles of subcutaneous peginterferon beta-1a and subcutaneous interferon beta-1a over 2 weeks in healthy subjects.
Investigating Axonal Damage in Multiple Sclerosis by Diffusion Tensor Spectroscopy.
Direct angiotensin AT2-receptor stimulation attenuates T-cell and microglia activation and prevents demyelination in experimental autoimmune encephalomyelitis in mice.
Natalizumab for the prevention of post-partum relapses in women with multiple sclerosis.
Association of IL4 and IL4R polymorphisms with multiple sclerosis susceptibility in Caucasian population: A meta-analysis.
Investigational Laquinimod Demonstrates Its Potential as a New Oral Treatment For RRMS
Tacrolimus potently inhibits human osteoclastogenesis induced by IL-17 from human monocytes alone and suppresses human Th17 differentiation.
The Submaximal Clinical Exercise Tolerance Test (SXTT) to Establish Safe Exercise Prescription Parameters for Patients with Chronic Disease and Disability.

Pages